Use of tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy effectiveness in cancer treatment
AssigneeFoundation Medicine, Inc.
InventorsRyon P. GRAF, Alexa SCHROCK, Richard Sheng Poe HUANG, Geoffrey R. OXNARD
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating an individual having a cancer, of treating or identifying an individual having cancer for a treatment, or stratifying individuals having a cancer for a treatment based on a tumor mutational burden (TMB) score or a TMB score and a microsatellite instability assessment.
Claims24
A method for treating an individual having a cancer, the method comprising:
- (a) determining a tumor mutational burden (TMB) score for a tumor biopsy sample obtained from the individual;
- and
- (b) treating the individual with an immune checkpoint inhibitor therapy if the TMB score is at least a threshold TMB score;
- wherein the cancer is a metastatic urothelial carcinoma, metastatic gastric adenocarcinoma, metastatic endometrial cancer, prostate cancer, or non-small cell lung cancer (NSCLC).
(canceled)
A method for identifying an individual having a cancer for treatment with an immune checkpoint inhibitor therapy comprising determining a tumor mutational burden (TMB) score for a tumor biopsy sample obtained from the individual, wherein if the TMB score is at least a threshold TMB score the individual is identified for treatment with an immune checkpoint inhibitor therapy, wherein the cancer is a metastatic urothelial carcinoma, metastatic gastric adenocarcinoma, metastatic endometrial cancer, prostate cancer, or non-small cell lung cancer (NSCLC).
Dependencies are inferred from the claim text.